Study Designs: DISCOVER 1 and DISCOVER 2 were phase 3, multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of TREMFYA^® administered q8w subcutaneously after starter doses at Week 0 and Week 4 (n=127 and n=248, respectively) or placebo (n=126 and n=246, respectively) with starter doses at Week 0, and then every 4 weeks in patients with active PsA (fulfilling CASPAR criteria) despite standard therapies (nonbiologic disease-modifying antirheumatic drugs [DMARDs], apremilast, and nonsteroidal anti-inflammatory drugs [NSAIDs]). A stable dose of 1 selected nonbiologic DMARD, corticosteroids, and NSAIDs were permitted but not required. In DISCOVER 1, eligible patients (≥18 years of age) had active PsA (swollen/tender joints ≥3, C-reactive protein [CRP] ≥0.3 mg/dL) for at least 6 months and included patients with prior biologic experience of ≤2 anti-TNFα treatments. Patients with other inflammatory diseases and those who had previously received Janus kinase (JAK) inhibitors or biologics other than TNFα inhibitors were excluded. In DISCOVER 2, eligible patients (≥18 years of age) had active PsA (swollen/tender joints ≥5, CRP ≥0.6 mg/dL) for at least 6 months and no prior JAK inhibitor or biologic experience. At Week 16, patients in all treatment groups who had <5% improvement from baseline in both swollen and tender joint counts were considered as meeting early escape and were allowed to initiate or increase the dose of one of the permitted concomitant medications up to the maximum dose allowed. The primary endpoint in DISCOVER 1 and DISCOVER 2 was ACR20 response at Week 24.^1,3,4